{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:32:40Z","timestamp":1773786760588,"version":"3.50.1"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is an active mediator of cytokine signaling in the pathogenesis of solid and hematologic malignancies. The seven-member STAT family is composed of latent cytoplasmic transcription factors that are activated by phosphorylation intertwined in a network with activation that ultimately leads to cell proliferation. An activated kinase enzyme phosphorylates one STAT factor or more, which shuttle to the nucleus to regulate gene expression, promoting cell survival. Somatic STAT3 mutations have been recently reported in large granular lymphocytic leukemia, aplastic anemia, and myelodysplastic syndrome. Furthermore, the relationship between BCL6 and STAT3 in diffuse large B-cell lymphomas, particularly on the activated B-cell subtype, needs to be further explored. The search for therapeutic STAT3 inhibitors that abrogate the JAK\/STAT pathway is currently under way. Targeting the STAT pathway, which seems to be critical in tumorigenesis, is promising for multiple malignancies including lymphoma and leukemia. In this paper, we review mechanisms of action, failures, and successes of STAT3 inhibitors.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0407","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T05:22:30Z","timestamp":1396675350000},"page":"536-544","source":"Crossref","is-referenced-by-count":62,"title":["STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia"],"prefix":"10.1093","volume":"19","author":[{"given":"Javier","family":"Munoz","sequence":"first","affiliation":[{"name":"Hematology-Oncology, Banner, MD Anderson Cancer Center, Gilbert, Arizona, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navjot","family":"Dhillon","sequence":"additional","affiliation":[{"name":"Hematology-Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie S.","family":"Watowich","sequence":"additional","affiliation":[{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"2021122308570705900_B1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2021122308570705900_B2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"2021122308570705900_B3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: Transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021122308570705900_B4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)81277-5","article-title":"STATs: Signal transducers and activators of transcription","volume":"84","author":"Ihle","year":"1996","journal-title":"Cell"},{"key":"2021122308570705900_B5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: From bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021122308570705900_B6","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122308570705900_B7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","article-title":"Targeting the interleukin-6\/Jak\/stat pathway in human malignancies","volume":"30","author":"Sansone","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes Dev"},{"key":"2021122308570705900_B9","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest"},{"key":"2021122308570705900_B10","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1073\/pnas.92.17.7779","article-title":"Interleukin 2 signaling involves the phosphorylation of Stat proteins","volume":"92","author":"Frank","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122308570705900_B11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.1201126","article-title":"Cutting edge: IL-10-mediated tristetraprolin induction is part of a feedback loop that controls macrophage STAT3 activation and cytokine production","volume":"189","author":"Gaba","year":"2012","journal-title":"J Immunol"},{"key":"2021122308570705900_B12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122308570705900_B13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"2021122308570705900_B14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/039463201202500105","article-title":"IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation","volume":"25","author":"Tete","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2021122308570705900_B15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1541-7786.MCR-07-2180","article-title":"Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas","volume":"6","author":"Brantley","year":"2008","journal-title":"Mol Cancer Res"},{"key":"2021122308570705900_B16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.semcancer.2012.02.008","article-title":"New insights into chronic inflammation-induced immunosuppression","volume":"22","author":"Kanterman","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"2021122308570705900_B17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","article-title":"Ups and downs: The STAT1:STAT3 seesaw of interferon and gp130 receptor signalling","volume":"19","author":"Regis","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"2021122308570705900_B18","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1182\/blood-2011-09-381483","article-title":"Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages","volume":"119","author":"Hutchins","year":"2012","journal-title":"Blood"},{"key":"2021122308570705900_B19","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"Van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B20","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122308570705900_B21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"2021122308570705900_B22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","article-title":"Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia","volume":"120","author":"Lierman","year":"2012","journal-title":"Blood"},{"key":"2021122308570705900_B23","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"key":"2021122308570705900_B24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrclinonc.2012.174","article-title":"Haematological cancer: Hit the lymphoma, JAK","volume":"9","author":"Kirk","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122308570705900_B25","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma","volume":"1","author":"Derenzini","year":"2011","journal-title":"Blood Cancer J"},{"key":"2021122308570705900_B26","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B27","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1200\/JCO.2012.44.0347","article-title":"Janus reveals another face: The biologic rationale for targeting Janus kinase 2 in lymphoma","volume":"30","author":"Mullally","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B28","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/art.37691","article-title":"Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors","volume":"64","author":"Yarilina","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021122308570705900_B29","first-page":"913","article-title":"JAK inhibitors in psoriasis: A promising new treatment modality","volume":"11","author":"Kwatra","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2021122308570705900_B30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2174\/138945011794751528","article-title":"The use of structural biology in Janus kinase targeted drug discovery","volume":"12","author":"Alicea-Vel\u00e1zquez","year":"2011","journal-title":"Curr Drug Targets"},{"key":"2021122308570705900_B31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B32","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"2021122308570705900_B33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.tips.2012.08.005","article-title":"JAK2 the future: Therapeutic strategies for JAK-dependent malignancies","volume":"33","author":"LaFave","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2021122308570705900_B34","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2010-12-319467","article-title":"FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia\/lymphoma","volume":"118","author":"Elliott","year":"2011","journal-title":"Blood"},{"key":"2021122308570705900_B35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/366580a0","article-title":"Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins","volume":"366","author":"Shuai","year":"1993","journal-title":"Nature"},{"key":"2021122308570705900_B36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1021\/ci200625q","article-title":"Molecular dynamics studies of the STAT3 homodimer: DNA complex: Relationships between STAT3 mutations and protein-DNA recognition","volume":"52","author":"Husby","year":"2012","journal-title":"J Chem Inf Model"},{"key":"2021122308570705900_B37","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood.V90.12.4749","article-title":"Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3","volume":"90","author":"Sato","year":"1997","journal-title":"Blood"},{"key":"2021122308570705900_B38","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1242\/jcs.03482","article-title":"Nucleocytoplasmic shuttling of persistently activated STAT3","volume":"120","author":"Herrmann","year":"2007","journal-title":"J Cell Sci"},{"key":"2021122308570705900_B39","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"2021122308570705900_B40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2567.2005.02091.x","article-title":"Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas","volume":"114","author":"Mitchell","year":"2005","journal-title":"Immunology"},{"key":"2021122308570705900_B41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0140-6736(66)90119-X","article-title":"Job's syndrome. Recurrent, \u201ccold\u201d, staphylococcal abscesses","volume":"1","author":"Davis","year":"1966","journal-title":"Lancet"},{"key":"2021122308570705900_B42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(74)92493-3","article-title":"Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections","volume":"1","author":"Hill","year":"1974","journal-title":"Lancet"},{"key":"2021122308570705900_B43","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308570705900_B44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"2021122308570705900_B45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/intimm\/dxn134","article-title":"Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: Lessons from a primary immunodeficiency","volume":"21","author":"Minegishi","year":"2009","journal-title":"Int Immunol"},{"key":"2021122308570705900_B46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM199903043400904","article-title":"Hyper-IgE syndrome with recurrent infections\u2014an autosomal dominant multisystem disorder","volume":"340","author":"Grimbacher","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122308570705900_B47","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1080\/10428190400004463","article-title":"Non-Hodgkin's lymphoma in Job's syndrome: A case report and literature review","volume":"45","author":"Leonard","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2021122308570705900_B48","first-page":"482","article-title":"Expression of STATs and their inhibitors SOCS and PIAS in brain tumors. In vitro and in vivo study","volume":"55","author":"Ehrmann","year":"2008","journal-title":"Neoplasma"},{"key":"2021122308570705900_B49","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr3134","article-title":"Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer","volume":"14","author":"Su","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2021122308570705900_B50","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2012-04-422527","article-title":"SOCS3 is an endogenous inhibitor of pathologic angiogenesis","volume":"120","author":"Stahl","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122308570705900_B51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000167859","article-title":"Epigenetic alterations in cholangiocarcinoma-sustained IL-6\/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing","volume":"79","author":"Isomoto","year":"2009","journal-title":"Digestion"},{"key":"2021122308570705900_B52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.it.2010.01.005","article-title":"The enigma of the role of protein inhibitor of activated STAT3 (PIAS3) in the immune response","volume":"31","author":"Yagil","year":"2010","journal-title":"Trends Immunol"},{"key":"2021122308570705900_B53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2036-2","article-title":"Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer","volume":"134","author":"Li","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308570705900_B54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9440(10)61666-5","article-title":"Estrogen receptor beta in prostate cancer: Brake pedal or accelerator?","volume":"159","author":"Signoretti","year":"2001","journal-title":"Am J Pathol"},{"key":"2021122308570705900_B55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543780802565791","article-title":"Targeting STAT3 in cancer: How successful are we?","volume":"18","author":"Yue","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122308570705900_B56","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1096\/fasebj.6.14.1426765","article-title":"Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction","volume":"6","author":"Levitzki","year":"1992","journal-title":"FASEB J"},{"key":"2021122308570705900_B57","first-page":"1270","article-title":"Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase\/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice","volume":"63","author":"Blaskovich","year":"2003","journal-title":"Cancer Res"},{"key":"2021122308570705900_B58","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/sj.onc.1208470","article-title":"Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity","volume":"24","author":"Sun","year":"2005","journal-title":"Oncogene"},{"key":"2021122308570705900_B59","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.4049\/jimmunol.168.12.6506","article-title":"Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes","volume":"168","author":"Natarajan","year":"2002","journal-title":"J Immunol"},{"key":"2021122308570705900_B60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1535-7163.261.3.3","article-title":"Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2021122308570705900_B61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/cb7001973","article-title":"An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects","volume":"2","author":"Siddiquee","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2021122308570705900_B62","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1073\/pnas.0409894102","article-title":"A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells","volume":"102","author":"Song","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122308570705900_B63","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1073\/pnas.0609757104","article-title":"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity","volume":"104","author":"Siddiquee","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122308570705900_B64","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.bmcl.2008.08.032","article-title":"Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening","volume":"18","author":"Hao","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"2021122308570705900_B65","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: A small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem Biol"},{"key":"2021122308570705900_B66","doi-asserted-by":"crossref","first-page":"32979","DOI":"10.1074\/jbc.M502694200","article-title":"A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells","volume":"280","author":"Turkson","year":"2005","journal-title":"J Biol Chem"},{"key":"2021122308570705900_B67","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.1533.3.12","article-title":"Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2021122308570705900_B68","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1021\/cb700186x","article-title":"Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target","volume":"2","author":"Timofeeva","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2021122308570705900_B69","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1073\/pnas.94.8.3801","article-title":"Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality","volume":"94","author":"Takeda","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122308570705900_B70","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1073\/pnas.0237137100","article-title":"STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity","volume":"100","author":"Welte","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"suppl","key":"2021122308570705900_B71","doi-asserted-by":"crossref","first-page":"3002a","DOI":"10.1200\/jco.2012.30.15_suppl.3002","article-title":"Phase I study of OPB51602, a small molecule inhibitor of STAT3 phosphorylation, in patients with refractory solid malignancies","volume":"30","author":"Goh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122308570705900_B72","doi-asserted-by":"crossref","first-page":"B56a","DOI":"10.1158\/1535-7163.TARG-11-B56","article-title":"Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors","volume":"10","author":"Kurzrock","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122308570705900_B73","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1038\/bcj.2013.63","article-title":"A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases","volume":"3","author":"Hayakawa","year":"2013","journal-title":"Blood Cancer J"},{"key":"2021122308570705900_B74","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","article-title":"First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy","volume":"2","author":"Sen","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122308570705900_B75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1126\/science.276.5312.589","article-title":"Control of inflammation, cytokine expression, and germinal center formation by BCL-6","volume":"276","author":"Dent","year":"1997","journal-title":"Science"},{"key":"2021122308570705900_B76","first-page":"2732","article-title":"Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma","volume":"53","author":"Ye","year":"1993","journal-title":"Cancer Res"},{"key":"2021122308570705900_B77","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma","volume":"331","author":"Offit","year":"1994","journal-title":"N Engl J Med"},{"key":"2021122308570705900_B78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.V86.1.45.bloodjournal86145","article-title":"BCL-6 protein is expressed in germinal-center B cells","volume":"86","author":"Cattoretti","year":"1995","journal-title":"Blood"},{"key":"2021122308570705900_B79","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood.V83.7.1757.1757","article-title":"Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma","volume":"83","author":"Lo Coco","year":"1994","journal-title":"Blood"},{"key":"2021122308570705900_B80","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2021122308570705900_B81","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.4049\/jimmunol.180.7.4805","article-title":"STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation","volume":"180","author":"Diehl","year":"2008","journal-title":"J Immunol"},{"issue":"suppl 1","key":"2021122308570705900_B82","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.clml.2011.03.029","article-title":"Non-Hodgkin's lymphoma: The old and the new","volume":"11","author":"Cabanillas","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122308570705900_B83","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12094-010-0527-3","article-title":"Epigenetic therapy of lymphoma using histone deacetylase inhibitors","volume":"12","author":"Cotto","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"2021122308570705900_B84","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"2021122308570705900_B85","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2012.45.6004","article-title":"Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-11-255","article-title":"Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma","volume":"11","author":"Ma","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122308570705900_B87","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/iub.607","article-title":"STAT3 interacts directly with Hsp90","volume":"64","author":"Prinsloo","year":"2012","journal-title":"IUBMB Life"},{"key":"2021122308570705900_B88","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res"},{"key":"2021122308570705900_B89","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"The Oncologist"},{"key":"2021122308570705900_B90","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B91","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1200\/JCO.2004.10.172","article-title":"Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma","volume":"22","author":"Schlette","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B92","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/bcj.2013.65","article-title":"Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation","volume":"3","author":"Andersson","year":"2013","journal-title":"Blood Cancer J"},{"key":"2021122308570705900_B93","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"2021122308570705900_B94","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/blood-2013-04-494930","article-title":"STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients","volume":"122","author":"Jerez","year":"2013","journal-title":"Blood"},{"key":"2021122308570705900_B95","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2013-08-521138","article-title":"STAT3 mutations and persistence of autoimmunity","volume":"122","author":"Schultz","year":"2013","journal-title":"Blood"},{"key":"2021122308570705900_B96","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1200\/JCO.2008.21.3264","article-title":"Targeting signal transducer and activator of transcription signaling pathway in leukemias","volume":"27","author":"Benekli","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B97","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2004.10.124","article-title":"The role of signal transducer and activator of transcription factors in leukemogenesis","volume":"22","author":"Sternberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122308570705900_B98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V99.1.252","article-title":"Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival","volume":"99","author":"Benekli","year":"2002","journal-title":"Blood"},{"key":"2021122308570705900_B99","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1080\/1042819031000116670","article-title":"Cross-talk between retinoic acid and STAT3 signaling pathways in acute promyelocytic leukemia","volume":"44","author":"Dong","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2021122308570705900_B100","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","article-title":"STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients","volume":"87","author":"Gouilleux-Gruart","year":"1996","journal-title":"Blood"},{"key":"2021122308570705900_B101","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1172\/JCI119869","article-title":"B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues","volume":"100","author":"Frank","year":"1997","journal-title":"J Clin Invest"},{"key":"2021122308570705900_B102","first-page":"1724","article-title":"BCR\/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats","volume":"10","author":"Frank","year":"1996","journal-title":"Leukemia"},{"key":"2021122308570705900_B103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","article-title":"Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity","volume":"123","author":"Hossain","year":"2014","journal-title":"Blood"},{"key":"2021122308570705900_B104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2013-11-537092","article-title":"STAT3: The \u201cAchilles\u201d heel for AML?","volume":"123","author":"Rezvani","year":"2014","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2013-0407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/5\/536\/41861925\/oncolo_19_5_536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/5\/536\/41861925\/oncolo_19_5_536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T22:19:33Z","timestamp":1689113973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/5\/536\/6399336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":104,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,4,4]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0407","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,1]]},"published":{"date-parts":[[2014,4,4]]}}}